Reshoring Manufacturing and Securing Cold-Chain Supply for Biopharma

This episode of BioPharm Drug Digest examines the reshoring of US biopharma manufacturing and the cold-chain strategies securing supply chains for biologics and regenerative medicines.

Register Free: https://www.biopharminternational.com/bp_w/Cold-Chain-Supply

Event Overview:

Global biopharmaceutical supply chains are realigning amid geopolitical instability, shifting trade policy, and fragility exposed by recent public health emergencies. Manufacturers are reshoring drug substance and product manufacturing to the United States, supported by new fill/finish capacity and modular platforms. Rising biologics and gene therapies are intensifying cold-chain demands, requiring ultra-low-temperature storage, real-time monitoring, and validated shipping lanes that preserve product integrity. Predictive analytics and Internet of Things tracking are improving visibility and reducing temperature excursions, as regulators scrutinize resilience and traceability. This episode of the BioPharm Drug Digest will examine how industry players are building a more resilient, domestic supply chain.

Key Learning Objectives:

• Evaluate the drivers behind reshoring and nearshoring of biopharmaceutical manufacturing to the United States.
• Assess cold-chain infrastructure requirements for biologics, cell and gene therapies, and other regenerative medicines.
• Identify digital tools and monitoring technologies that improve supply chain visibility and reduce temperature excursions.
• Establish strategies for building more resilient, domestically anchored supply networks.

Who Should Attend:

• Supply Chain and Logistics Executives
• Manufacturing and Operations Leaders
• Cold-Chain and Cell/Gene Therapy Logistics Specialists
• Regulatory Affairs and Quality Assurance Professionals

Featured Speakers Coming Soon!

Register Free: https://www.biopharminternational.com/bp_w/Cold-Chain-Supply